Fosun Pharma (02196): HLX13 initiated phase I/III clinical trial in China for first-line treatment of unresectable advanced hepatocellular carcinoma (HCC) patients.

Zh tng cijng APP xn, f xng y yo (02196) gngb, jnr, gngs kngg zgngs shnghi f hng hn ln shngw jsh gfn yuxin gngs jq kngg zgngs zzh ynf de y p m dn kng shngw lis yo HLX13 (chngz kng CTLA-4 qun rn dn k chun kng t zhsh y, y xi jinchng HLX13) yxin zhl bk qich de wnq xb bng (HCC) hunzh y zhnggu jngni qdng I/III q lnghun shyn.